(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
18 January 2024 (18.01.2024)

WIPO | PCT

(10) International Publication Number
WO 2024/012584 A1

(51) International Patent Classification:
A61K 39/395 (2006.01)

(21) International Application Number:
PCT/CN2023/107563

(22) International Filing Date:
14 July 2023 (14.07.2023)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PCT/CN2022/105904
15 July 2022 (15.07.2022) CN
PCT/CN2023/084985
30 March 2023 (30.03.2023) CN

(71) Applicant: **BEIGENE SWITZERLAND GMBH** [CH/CH]; Aeschengraben 27, 4051 Basel (CH).

(72) Inventor; and

(71) Applicant *(for SC only)*: **CHEN, Xin** [CN/CN]; No.30 Science Park Road, Zhongguancun Life Science Park, Changping District, Beijing 102206 (CN).

(72) Inventors: **DING, Xiao**; No.30 Science Park Road, Zhongguancun Life Science Park, Changping District, Beijing 102206 (CN). **REN, Zhiying**; No.30 Science Park Road, Zhongguancun Life Science Park, Changping District, Beijing 102206 (CN). **SONG, Jing**; No.30 Science Park Road, Zhongguancun Life Science Park, Changping District, Beijing 102206 (CN). **SUN, Jian**; No.30 Science Park Road, Zhongguancun Life Science Park, Changping District, Beijing 102206 (CN). **XUE, Liu**; No.30 Science Park Road, Zhongguancun Life Science Park, Changping District, Beijing 102206 (CN). **YANG, Xiao**; No.30 Science Park Road, Zhongguancun Life Science Park, Changping District, Beijing 102206 (CN). **ZHANG, Jing**; No.30 Science Park Road, Zhongguancun Life Science Park, Changping District, Beijing 102206 (CN).

(74) Agent: **WU, FENG & ZHANG**; 3FL, Building 4, Yard 38, LinFengErLu Road, Greenland Central Square, Haidian District, Beijing 100089 (CN).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*

WO 2024/012584 A1

(54) Title: METHODS OF CANCER TREATMENT USING ANTI-TIGIT ANTIBODIES

(57) Abstract: Provided are methods of treating cancer or increasing, enhancing, or stimulating an immune response with antibodies that specifically bind to TIGIT (T cell immunoreceptor with Ig and ITIM domains, WUCAM or Vstm3) and antigen-binding fragments thereof in combination with an anti-PD1 antibody.